-
1 Comment
Hanall Biopharma Co.,Ltd is currently in a long term downtrend where the price is trading 23.4% below its 200 day moving average.
From a valuation standpoint, the stock is 56.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 13.4.
Hanall Biopharma Co.,Ltd's total revenue sank by 16.6% to $22B since the same quarter in the previous year.
Its net income has increased by 0.8% to $6B since the same quarter in the previous year.
Finally, its free cash flow grew by 128.7% to $3B since the same quarter in the previous year.
Based on the above factors, Hanall Biopharma Co.,Ltd gets an overall score of 2/5.
| ISIN | KR7009420001 |
|---|---|
| Sector | Healthcare |
| Exchange | KO |
| CurrencyCode | KRW |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | 1T |
|---|---|
| PE Ratio | None |
| Target Price | 48000 |
| Beta | 0.81 |
| Dividend Yield | None |
Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, toxic liver disease, chronic hepatitis, liver cirrhosis, male pattern baldness, functional dyspepsia, diabetes, bacterial infections, peripheral vascular disorders, hypertension, chronic heart failure, skin diseases, hypoproteinemia, diabetic polyneuritis, ulcers, high blood pressure, arthritis, endocrine disorders, spasms, insomnia, muscle pain, hypoproteinemia, gastroesophageal reflux disease, allergic rhinitis, conjunctivitis, dermatitis, chronic urticaria, cholesterol cholelithiasis, gastritis, neurological diseases, erectile dysfunction, hyperphosphatemia, urinary tract infection, spastic paralysis, fungal infections, dysmenorrhea, hypercholesterolemia, constipation, abdominal distension, abdominal fermentation in the intestines, neuralgia, capillary weakness, post-phlebitis syndrome, irritable bowel syndrome, spastic colon, and hemorrhoids, as well as vitamin D, vitamin B1, vitamin B12, and calcium deficiency. It develops products in the fields of ophthalmology, immunology, oncology, and neurology, such as HL192 for Parkinson's disease; HL036 for dry eye disease; HL161 for myasthenia gravis, thyroid eye disease, warm autoimmune hemolytic anemia, neuromyelitis optica, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, and graves' disease; and HL187 and HL186 for immuno-oncology. The company was founded in 1973 and is headquartered in Daejeon, South Korea.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 009420.KO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
